Monogram Biosciences, Inc., a life science company, develops molecular diagnostic products for the treatment of infectious diseases, cancer, and other diseases in the United States. The company offers products for HIV testing, including GeneSeq HIV, PhenoSense HIV Entry, and PhenoSense HIV Integrase for measuring resistance of a patient?s HIV to anti-viral drugs; Geneseq HIV, Geneseq HIV Entry, and Geneseq HIV Integrase for evaluating the genetic sequences of a patient?s HIV for the evidence of drug resistance; and PhenoScreen for the identification of potential drug candidates. It also offers PhenoSense HIV Antibody Neutralization for testing patients? blood samples for the presence of antibodies that neutralize the HIV virus and Trofile Co-Receptor Tropism that identifies the co-receptor the patient?s virus uses to enter cells. In addition, it offers HERmark breast cancer assay based on the VeraTag technology platform for guiding the treatment of cancer patients. Monogram Biosciences focuses on the development of assays, including HER1, HER2, and HER3 protein and other to evaluate their correlation with resistance to herceptin treatment. It serves physicians and pharmaceutical companies. Monogram Biosciences has collaboration with Pfizer Inc. The company was incorporated in 1995 and is headquartered in South San Francisco, California.
3 year weekly...